[Development of mixed infection in patient with nephrotic syndrome on immunosuppressive therapy].
V V
VV
Popova
E M
EM
Shilov
B M
BM
Kornev
N G
NG
Miroshnichenko
M D
MD
Romanova
D000328:Adult; D000908:Antibodies, Fungal / Q000032:analysis; D000914:Antibodies, Viral / Q000032:analysis; D000935:Antifungal Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D001228:Aspergillosis / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology; D001230:Aspergillus / Q000276:immunology; D003587:Cytomegalovirus / Q000235:genetics / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology; D004279:DNA, Viral / Q000032:analysis; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008172:Lung Diseases, Fungal / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology; D008297:Male; D009404:Nephrotic Syndrome / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D009894:Opportunistic Infections / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology
D000908:Antibodies, Fungal; D000914:Antibodies, Viral; D000935:Antifungal Agents; D000998:Antiviral Agents; D004279:DNA, Viral; D007166:Immunosuppressive Agents